ScaleReady Introduces the Cue® Cell Processing System From Fresenius Kabi

Rhea-AI Summary

ScaleReady, a joint venture involving Bio-Techne (NASDAQ: TECH), announces the launch of the Cue Cell Processing System, designed exclusively for cell and gene therapy organizations. This innovative system automates complex, labor-intensive tasks, enhancing precision in cell processing workflows. Cue is customizable, ensuring that final formulations meet specifications consistently. Available in the U.S., Canada, and Europe, it also supports requests for regulatory documentation for advanced applications. This launch positions ScaleReady as a leader in the evolving market of cell and gene therapies.

Positive

• Launch of the Cue Cell Processing System enhances manufacturing efficiency for cell and gene therapy.
• Cue provides automation for labor-intensive tasks, leading to improved precision in processing.
• The system is customizable, ensuring consistent formulation and final concentration.

Negative

• None.

New Technology Platform Replaces Manual Processes and Brings Unmatched Precision and Efficiency to Cell and Gene Therapy Organizations

ST. PAUL, Minn.--(BUSINESS WIRE)-- ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi and Wilson Wolf, announced today the market launch of the Cue Cell Processing System from Fresenius Kabi, available exclusively from ScaleReady.

Cue, an automated small volume cell processing system, can precisely concentrate, wash, dilute, formulate and aliquot cell suspensions. Cue automates critical labor-intensive and highly variable tasks in the manufacturing workflow. This automated and functionally closed system will provide cell and gene therapy developers a much-needed solution for commercial scale cGMP final fill and finish.

“Our engineers developed Cue as a breakthrough technology for small volume cell processing,” said Dr. Christian Hauer, president of MedTech at Fresenius Kabi. “We are committed to innovating for the unique needs of the cell and gene therapy community. Cue combines novel closed system syringe pumps with best-in-class hardware and software — an exciting addition to the ScaleReady portfolio.”

Therapy developers are often required to modify their manufacturing processes to fit the constraints of existing automated equipment. Cue offers the flexibility and reliability demonstrated by Fresenius Kabi’s Lovo^® Cell Processing System. Fully customizable mid-procedure sampling and recalculation enables the system to fit easily into any process, ensuring final concentration and formulations are achieved every time.

Starting today, Cue is available exclusively from ScaleReady in the U.S., Canada and Europe with other countries soon to follow. Cue has a laboratory use indication. For companies looking to use Cue for applications requiring regulatory clearance or approval, they may request technical documentation from Fresenius Kabi to support their submissions to local health regulators.

To learn more about Cue, visit www.choosecue.com or email ScaleReady at info@scaleready.com.

About ScaleReady

ScaleReady (www.scaleready.com) is bringing the future of cell and gene therapies to life with the most powerful and versatile manufacturing platform in the industry. ScaleReady delivers rapid expansion of T-cells at scale—reducing complexity and cost, while providing superior repeatability and cell quality. Founded in 2020, ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together tools and technologies for cell culture, cell activation, gene editing and cell processing from each founding partner.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005003/en/

Matt Kuhn

Fresenius Kabi

matt.kuhn@fresenius-kabi.com

1-847-220-3033

ScaleReady

Katy O'Neill

Beehive Strategic Communication

koneill@beehivepr.biz

862-219-0105

Source: ScaleReady

FAQ

What is the Cue Cell Processing System launched by ScaleReady?

The Cue Cell Processing System is an automated device that improves precision and efficiency in cell and gene therapy manufacturing.

When was the Cue Cell Processing System launched?

The Cue Cell Processing System was launched recently by ScaleReady.

Where is the Cue Cell Processing System available?

The Cue Cell Processing System is available in the U.S., Canada, and Europe.

How does the Cue Cell Processing System enhance cell processing?

Cue automates critical tasks, improving precision, customization, and efficiency in cell and gene therapy workflows.

Who developed the Cue Cell Processing System?

The Cue Cell Processing System was developed by Fresenius Kabi as part of the ScaleReady joint venture.